The beneficial effects of renin angiotensin aldosterone system (RAAS) blockade on residual renal function (RRF) in patients who have just initiated hemodialysis (HD) have been inconclusive. In this ...

Renin–angiotensin–aldosterone system (RAAS) inhibitors are antihypertensive agents with conflicting results on protective effects against some types of cancer. In light of these controversies, we ...

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

A recent study posted to the medRxiv* preprint server investigated the association of renin-angiotensin-aldosterone system (RAAS)-mediated hypertension (HT) with coronavirus disease 2019 (COVID-19).

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system (RAAS) inhibitors conferred reduced risks for starting dialysis or needing ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

Investigators found no definitive benefit of dual RAAS blockade in preventing kidney failure in patients with ADPKD. For patients with autosomal dominant polycystic kidney disease (ADPKD), intensive ...

Utility of the Breast Cancer Index (BCI) in the clinical practice. CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial ...